{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:27:04Z","timestamp":1791163624423,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,9,22]],"date-time":"2007-09-22T00:00:00Z","timestamp":1190419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1007\/s12016-007-8028-z","type":"journal-article","created":{"date-parts":[[2007,9,21]],"date-time":"2007-09-21T15:51:01Z","timestamp":1190389861000},"page":"124-128","source":"Crossref","is-referenced-by-count":75,"title":["Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?"],"prefix":"10.1007","volume":"34","author":[{"given":"Claudio","family":"Galarza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel J.","family":"Tob\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Zurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n D.","family":"Mantilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Pineda-Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rojas-Villarraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Manuel","family":"Anaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,9,22]]},"reference":[{"key":"8028_CR1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2005.06.011","volume":"5","author":"P Youinou","year":"2006","unstructured":"Youinou P et al (2006) B lymphocytes on the front line of autoimmunity. Autoimmun Rev 5:215\u2013221","journal-title":"Autoimmun Rev"},{"key":"8028_CR2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435\u2013445","journal-title":"Blood"},{"key":"8028_CR3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","volume":"48","author":"D Shan","year":"2000","unstructured":"Shan D, Ledbetter JA, Press OW (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673\u2013683","journal-title":"Cancer Immunol Immunother"},{"key":"8028_CR4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","volume":"7","author":"DA Einfeld","year":"1988","unstructured":"Einfeld DA et al (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7:711\u2013717","journal-title":"EMBO J"},{"key":"8028_CR5","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1016\/S0021-9258(18)60461-2","volume":"264","author":"MA Valentine","year":"1989","unstructured":"Valentine MA et al (1989) Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 264:11282\u201311287","journal-title":"J Biol Chem"},{"key":"8028_CR6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"KC Anderson","year":"1984","unstructured":"Anderson KC et al (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63:1424\u20131433","journal-title":"Blood"},{"key":"8028_CR7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4049\/jimmunol.135.2.973","volume":"135","author":"TF Tedder","year":"1985","unstructured":"Tedder TF et al (1985) The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135:973\u2013979","journal-title":"J Immunol"},{"key":"8028_CR8","first-page":"195","volume":"14D","author":"TF Tedder","year":"1990","unstructured":"Tedder TF et al (1990) The CD20 surface molecule of B lymphocytes functions as a calcium channel. J Cell Biochem 14D:195","journal-title":"J Cell Biochem"},{"key":"8028_CR9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","volume":"69","author":"OW Press","year":"1987","unstructured":"Press OW et al (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584\u2013591","journal-title":"Blood"},{"key":"8028_CR10","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793\u20132806","journal-title":"Arthritis Rheum"},{"key":"8028_CR11","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572\u20132581","journal-title":"N Engl J Med"},{"key":"8028_CR12","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390\u20131400","journal-title":"Arthritis Rheum"},{"key":"8028_CR13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","volume":"64","author":"JE Gottenberg","year":"2005","unstructured":"Gottenberg JE et al (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:913\u2013920","journal-title":"Ann Rheum Dis"},{"key":"8028_CR14","first-page":"2109","volume":"32","author":"J Higashida","year":"2005","unstructured":"Higashida J et al (2005) Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol 32:2109\u20132115","journal-title":"J Rheumatol"},{"key":"8028_CR15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bmt.1704570","volume":"34","author":"J Moore","year":"2004","unstructured":"Moore J et al (2004) A phase II study of rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant 34:241\u2013247","journal-title":"Bone Marrow Transplant"},{"key":"8028_CR16","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0091270005277075","volume":"45","author":"CM Ng","year":"2005","unstructured":"Ng CM et al (2005) Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45:792\u2013801","journal-title":"J Clin Pharmacol"},{"key":"8028_CR17","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","volume":"50","author":"JH Anolik","year":"2004","unstructured":"Anolik JH et al (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50:3580\u20133590","journal-title":"Arthritis Rheum"},{"key":"8028_CR18","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.10541","volume":"46","author":"MJ Leandro","year":"2002","unstructured":"Leandro MJ et al (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46:2673\u20132677","journal-title":"Arthritis Rheum"},{"key":"8028_CR19","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580\u20132589","journal-title":"Arthritis Rheum"},{"key":"8028_CR20","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","volume":"54","author":"KG Smith","year":"2006","unstructured":"Smith KG et al (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54:2970\u20132982","journal-title":"Arthritis Rheum"},{"key":"8028_CR21","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar1954","volume":"8","author":"M Vigna-Perez","year":"2006","unstructured":"Vigna-Perez M et al (2006) Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8:R83","journal-title":"Arthritis Res Ther"},{"key":"8028_CR22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2006.01.041","volume":"148","author":"M Willems","year":"2006","unstructured":"Willems M et al (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148:623\u2013627","journal-title":"J Pediatr"},{"key":"8028_CR23","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe J et al (2005) Rituximab treatment in patients with primary Sjogren\u2019s syndrome: an open-label phase II study. Arthritis Rheum 52:2740\u20132750","journal-title":"Arthritis Rheum"},{"key":"8028_CR24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/art.11109","volume":"49","author":"BG Somer","year":"2003","unstructured":"Somer BG et al (2003) Improvement in Sjogren\u2019s syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 49:394\u2013398","journal-title":"Arthritis Rheum"},{"key":"8028_CR25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/keh248","volume":"43","author":"M Voulgarelis","year":"2004","unstructured":"Voulgarelis M et al (2004) Combined therapy with rituximab plus cyclophosphamide\/doxorubicin\/vincristine\/prednisone (CHOP) for Sjogren\u2019s syndrome-associated B-cell aggressive non-Hodgkin\u2019s lymphomas. Rheumatology (Oxford) 43:1050\u20131053","journal-title":"Rheumatology (Oxford)"},{"key":"8028_CR26","first-page":"441","volume-title":"Autoinmunidad y Enfermedad Autoinmune","author":"GJ Tobon","year":"2005","unstructured":"Tobon GJ, Galarza C, Anaya JM (2005) Rituximab en enfermedades autoinmunes. In: Anaya JM et al (eds) Autoinmunidad y Enfermedad Autoinmune. Corporaci\u00f3n para Investigaciones Biol\u00f3gicas, Medellin, pp 441\u2013452"},{"key":"8028_CR27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"8028_CR28","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271\u20131277","journal-title":"Arthritis Rheum"},{"key":"8028_CR29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C et al (2002) Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554\u2013558","journal-title":"Ann Rheum Dis"},{"key":"8028_CR30","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.1780330811","volume":"33","author":"WP Arend","year":"1990","unstructured":"Arend WP et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129\u20131134","journal-title":"Arthritis Rheum"},{"key":"8028_CR31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/art.1780370404","volume":"37","author":"Anonymous","year":"1994","unstructured":"Anonymous (1994) Reduced joint counts in rheumatoid arthritis clinical trials. American College of Rheumatology Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 37:463\u2013464","journal-title":"Arthritis Rheum"},{"key":"8028_CR32","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C et al (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630\u2013640","journal-title":"Arthritis Rheum"},{"key":"8028_CR33","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","volume":"61","author":"WJ Pichler","year":"2006","unstructured":"Pichler WJ (2006) Adverse side-effects to biological agents. Allergy 61:912\u2013920","journal-title":"Allergy"},{"key":"8028_CR34","doi-asserted-by":"crossref","first-page":"S378","DOI":"10.1002\/art.10773","volume":"48","author":"MJ Leandro","year":"2003","unstructured":"Leandro MJ et al (2003) Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum 48:S378","journal-title":"Arthritis Rheum"},{"key":"8028_CR35","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","volume":"48","author":"G Cambridge","year":"2003","unstructured":"Cambridge G et al (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48:2146\u20132154","journal-title":"Arthritis Rheum"},{"key":"8028_CR36","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","volume":"99","author":"G Cartron","year":"2002","unstructured":"Cartron G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754\u2013758","journal-title":"Blood"},{"key":"8028_CR37","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","volume":"64","author":"S Dall\u2019Ozzo","year":"2004","unstructured":"Dall\u2019Ozzo S et al (2004) Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration\u2013effect relationship. Cancer Res 64:4664\u20134669","journal-title":"Cancer Res"},{"key":"8028_CR38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","volume":"48","author":"JH Anolik","year":"2003","unstructured":"Anolik JH et al (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455\u2013459","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-007-8028-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-007-8028-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-007-8028-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T06:23:55Z","timestamp":1684045435000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-007-8028-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,22]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["8028"],"URL":"https:\/\/doi.org\/10.1007\/s12016-007-8028-z","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,22]]}}}